Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

By sjmartinez • May 8, 2025

Özgüroğlu M, Goldman JW, Chen Y, Garassino MC, Medic N, Mann H, Chugh P, Dalvi T, Paz-Ares L. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May 7:1-13. doi: 10.1080/14796694.2025.2491297. Epub ahead of print. PMID: 40331625.

Tags: Adverse events, durvalumab, Extensive-stage small-cell lung cancer, health-related quality of life, Hematology/Oncology, immune checkpoint inhibitors, patient experience, patient-reported adverse events, patient-reported outcomes, Publications

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets

Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim DM,[...]

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Zeng W, Liu CC, Li S, Zhou Y, Stackpole ML, Xiao Y, Hu R, Tang C, Liu Q, Zeng W, Yeh A, Melehy A, Tran[...]

Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

López JCV, Ho A, Hughes KS, Bardia A, Vidula N. Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to[...]